The ESPRIT Study: Estrogen Suppression and Perfusion Reserve With Aromatase-Inhibitor Treatment in Premenopausal Women With Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Regadenoson (Primary) ; Adenosine
- Indications Heart disorders
- Focus Therapeutic Use
- Acronyms ESPRIT
- 26 Nov 2019 Planned End Date changed from 1 Dec 2020 to 12 Mar 2020.
- 26 Nov 2019 Planned primary completion date changed from 1 Dec 2019 to 12 Mar 2020.
- 26 Nov 2019 Status changed from recruiting to active, no longer recruiting.